Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription drugs for hospital acute care, gastroenterology, and oncology markets. The company's FDA-approved portfolio includes seven marketed brands serving these concentrated prescriber bases through targeted sales forces, including Acetadote for acetaminophen poisoning, Caldolor as the first injectable NSAID, Sancuso as a transdermal patch for chemotherapy-induced nausea, and others, while advancing the investigational drug ifetroban through clinical trials. Cumberland generates revenue from direct product sales in the United States through pharmaceutical wholesalers and from international licensing arrangements with partners who pay upfront fees, milestones, and royalties, while leveraging its commercial infrastructure and pursuing growth through label expansions, acquisitions of underutilized FDA-approved drugs, and strategic partnerships.